Author
By Kevin Outterson The American Society for Law, Medicine & Ethics (ASLME) is pleased to announce the 4th annual bioIP Faculty Workshop on Friday April 26, 2019, at Boston University. The Workshop offers a unique…
By Kevin Outterson BU is hiring in health law this year, hopefully a lateral with tenure. Anna di Robilant chairs the committee. Any other law schools hiring in HL this year?
By Kevin Outterson Ironic that the leading argument against the President’s Executive Order 13768 on Sanctuary Cities is none other than the states’ rights / coercion arguments that convinced seven Justices to make the Medicaid expansion voluntary.…
CALL FOR PARTICIPATION – ‘Research for Impact’ & the G20: How can global health innovation drive sustainable development? Date: April 28th 2017Location: Central BerlinTime: 10:00-17:00 The G20 has underlined its commitment to contribute to the…
By Kevin Outterson Nick Bagley and I have an op-ed in today’s New York Times calling for serious economic incentives for antibiotics, delinking revenues from sales volumes with a $4 billion prize system. From the…
By Kevin Outterson Yesterday US HHS announced a new global partnership to fund pre-clinical antibiotic R&D, coordinated by the Boston University School of Law. The partnership is known as CARB-X, which is the abbreviation for the…
By Kevin Outterson The Faculty of Law at the University of Cambridge is currently advertising an excellent research opportunity for early career scholars interested in intellectual property and genomics (annual salary: £28,695-£37,394). Applications close on…
By Kevin Outterson Or so we claim in this month’s WHO Bulletin. Resistance is a global common pool problem requiring simultaneous action on three fronts: access to effective antibiotics (many more deaths from susceptible bacterial…
This new post by Kevin Outterson appears on the Health Affairs Blog, as part of part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January…
By Kevin Outterson A short article in the New Yorker on my favorite topic – business models for antibiotic use and innovation.
